TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01914484
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).~No intra-patient dose-escalation will occur. JAK inhibitor
Study: NCT03719313
Drug: Lonafarnib
Normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lonafarnib (LNF) 50 mg BID
Study: NCT03719313
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (RTV) 100 mg BID
Study: NCT03719313
Drug: PEG IFN-alfa-2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG IFN alfa-2a 180 mcg QW
Study: NCT03719313
Drug: Placebo Lonafarnib
Normalized name: lonafarnib
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo
Study: NCT03719313
Drug: Placebo Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo
Study: NCT00446433
Drug: CC-5013
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03155945
Drug: Olorinab
Normalized name: Olorinab
DrugBank: Olorinab (DB14998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olorinab active treatment for 8 weeks.
Study: NCT04494984
Drug: INM005
Normalized name: INM005
DrugBank: INM005 (DB16499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
Study: NCT01573780
Drug: Smac mimetic TL32711
Normalized name: Apg-1387 (smac mimetic)
DrugBank: APG-1387 (DB16095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01573780
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01642238
Drug: Ticagrelor + ASA + Bivalirudin
Normalized name: Ticagrelor
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Study: NCT01642238
Drug: Clopidogrel + ASA + Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Study: NCT03812965
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 2 units/point of botulinum toxin type A
Study: NCT01838642
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
Study: NCT01495585
Drug: Lonafarnib
Normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially approved products used to test the research hypothesis
Study: NCT03075670
Drug: N9-GP
Normalized name: GPS
DrugBank: Galinpepimut-S (DB17271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 50 IU/kg for intravenous (i.v.) injection
Study: NCT00110058
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00110058
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00110058
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00110058
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02325011
Drug: Sativex® and fluconazole concomitantly (Treatment B)
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.~Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose.
Study: NCT00001731
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00150046
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02028988
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00656630
Drug: Acamprosate
Normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
Study: NCT00656630
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg capsule, Once daily, 1 week duration
Study: NCT02665208
Drug: Nicotine Replacement Therapies
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
Study: NCT02665416
Drug: Selicrelumab
Normalized name: Selicrelumab
DrugBank: Selicrelumab (DB14958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selicrelumab will be provided as concentrate for solution to be administered via SC injection
Study: NCT02665416
Drug: Vanucizumab
Normalized name: Vanucizumab
DrugBank: Vanucizumab (DB12317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanucizumab will be provided as solution to be administered via IV infusion.
Study: NCT02665416
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered via IV infusion.
Study: NCT02753699
Drug: Alisporivir
Normalized name: Alisporivir
DrugBank: Alisporivir (DB12139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention of interest; follow-up after ALV-active study
Study: NCT06310850
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be administered 0.15 mg kg-1 intravenous ketamine (The sample provided contains equal proportions of two enantiomers, S and R ketamine hydrochloride.) 3 minutes before thoracic epidural catheter placement.
Study: NCT05492669
Drug: Lidocaine Hydrochloride, Injectable
Normalized name: Lidocaine Hydrochloride, Injectable
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
Study: NCT00456716
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg po bid
Study: NCT01787578
Drug: Sobetirome
Normalized name: Sobetirome
DrugBank: Sobetirome (DB07425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg or 100 mcg once-daily oral
Study: NCT03978364
Drug: Azacitidine combined HHT
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days
Study: NCT03978364
Drug: Azacitidine regimen
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle
Study: NCT03402438
Drug: Fulacimstat (BAY1142524)
Normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 25 mg immediate-release tablet BAY1142524
Study: NCT00191854
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
Study: NCT00191854
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg/m2, IV, every 14 days x 8 cycles
Study: NCT00191854
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
Study: NCT00191854
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2, IV, every 14 days x 8 cycles
Study: NCT04248595
Drug: Homoharringtonine
Normalized name: Homoharringtonine
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
Study: NCT04248595
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
Study: NCT01076504
Drug: Amrubicin
Normalized name: amrubicin
DrugBank: Amrubicin (DB06263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
Study: NCT01076504
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=5 IV, Day 1 of each 3-week treatment cycle
Study: NCT01076504
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg SQ on Day 4 of each 3 week treatment cycle
Study: NCT00915512
Drug: Paliperidone extended-release (ER)
Normalized name: paliperidone Extended Release Oral Tablet
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
Study: NCT04275596
Drug: 2QR complex
Normalized name: Hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of topical gel containing 2QR complex on the anal wound until complete wound healing
Study: NCT02321462
Drug: Eziclen
Normalized name: Esiclene
DrugBank: Formebolone (DB01569)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
Study: NCT02196324
Drug: serlopitant
Normalized name: Serlopitant
DrugBank: Serlopitant (DB12973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK1 receptor antagonist
Study: NCT03571919
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous bolus of lidocaine (1.25 mg/kg) and then infusion at 1 mg/kg/hr
Study: NCT00571506
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg tablets by mouth daily for 3 months
Study: NCT00571506
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 30 mg tablet by mouth once daily
Study: NCT03367377
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT01846975
Drug: IV Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
Study: NCT02724904
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Treatment
Study: NCT02724904
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard Treatment
Study: NCT02806050
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: all patients will be treated with palbociclib, on a 3 weeks on, 1 week off cycle until progression
Study: NCT02806050
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all patients will be treated with Letrozole daily until progression
Study: NCT02265822
Drug: midazolam in children premedication
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00558103
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration
Study: NCT00558103
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration
Study: NCT02469116
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02469116
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02469116
Drug: Pegylated G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01519856
Drug: piribedil (Clarium)
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets, 50 mg
Study: NCT01183169
Drug: Alisporivir
Normalized name: Alisporivir
DrugBank: Alisporivir (DB12139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALV 200 mg soft gel capsules administered orally
Study: NCT01183169
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
Study: NCT01183169
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study: NCT00089570
Drug: terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01719185
Drug: Phentermine and B12
Normalized name: phentermine and topiramate
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01719185
Drug: Phentermine
Normalized name: Phentermine
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00692770
Drug: Nexavar (Sorafenib, BAY43-9006)
Normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice daily (BID)
Study: NCT02769702
Drug: Acthar
Normalized name: Acthar
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acthar 80 IU SC twice a week
Study: NCT05410470
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00397800
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00161707
Drug: Aerosolized, Recombinant Alpha 1-Antitrypsin
DrugBank: Recombinant alpha 1-antitrypsin (DB05481)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00917891
Drug: dapivirine
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks
Study: NCT00175890
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.
Study: NCT01889680
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression
Study: NCT01889680
Drug: ziv-aflibercept
Normalized name: Ziv-Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 mg/kg IV day 1 every 14 days for 6 cycles (induction regimen); 4 mg/kg IV day 1 every 14 days until disease progression (continuation regimen)
Study: NCT04431791
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral regorafenib
Study: NCT04431791
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral fruquintinib
Study: NCT01930292
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.
Study: NCT01930292
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.
Study: NCT02258204
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.
Study: NCT00326664
Drug: Cediranib Maleate
Normalized name: maleate
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00424151
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00587379
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg atorvastatin pill daily
Study: NCT00563238
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
Study: NCT00989833
Drug: budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 yg x 1
Study: NCT00989833
Drug: terbutaline
Normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 mg as-needed
Study: NCT00989833
Drug: budesonide/formoterol
Normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 160/4.5 yg as-needed
Study: NCT03625388
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Film coated tablet contains dasatinib monohydrate
Study: NCT02181933
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02181933
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02181933
Drug: Lamivudine (3TC)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00962845
Drug: hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg twice daily in the first ten patients. If the first ten patients tolerate this dosage schedule (200 mg bid) without significant side effects (Grade 3 or greater gastrointestinal upset, skin toxicity, myopathy or any visual disturbances whatsoever), the second ten patients will be enrolled at a dose of 400 mg bid
Study: NCT01323478
Drug: Vortioxetine (Lu AA21004)
Normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 or 20 mg/day; tablets; orally
Study: NCT04666805
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/d, oral administration
Study: NCT04666805
Drug: Toremifene
Normalized name: Toremifene
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/d, oral administration
Study: NCT04666805
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet (1 mg) per day, oral administration
Study: NCT00244712
Drug: emtricitabine/tenofovir
Normalized name: EMTRICITABINE/TENOFOVIR
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
Study: NCT00244712
Drug: abacavir/lamivudine
Normalized name: ABACAVIR/LAMIVUDINE
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
Study: NCT00684606
Drug: Oxytocin IV
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 miu/1000ml Glu/Saline